Search peptides, terms, sources/
Research source · 2021

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
12 people with Barth syndrome randomised; 10 continued into the open-label part
Sample size
12
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Very small, crossover design in an ultra-rare disease. One author is employed by Stealth BioTherapeutics, the developer. The open-label part has no control group. Abstract read via Europe PMC; full text not read.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.